Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Posted by Hanz Christensen on Nov 13th, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,200,000 shares, a growth of 675.7% from the October 15th total of 154,700 shares. Based on an average daily trading volume, of 6,330,000 shares, the short-interest ratio is currently 0.2 days.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. 8.06% of the stock is owned by hedge funds and other institutional investors.

Aptevo Therapeutics Stock Performance

NASDAQ:APVO opened at $0.27 on Wednesday. Aptevo Therapeutics has a 52 week low of $0.14 and a 52 week high of $10.80. The stock’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.45.

Wall Street Analyst Weigh In

Several analysts recently commented on APVO shares. StockNews.com began coverage on Aptevo Therapeutics in a report on Thursday, November 7th. They set a “sell” rating on the stock. Roth Mkm cut their target price on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

View Our Latest Stock Report on APVO

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.